I-Estrogen Crash: Ukwelapha ukuKhulelwa kwexesha lokuqala
Unyaka ngamnye amawaka amabhinqa aphakathi kweminyaka eyi-15 no-44 afumana "i-Estrogen Crash", ngokukhawuleza kwehla kumazinga e-estrogen eshiya abasetyhini kwimigca yokuqeda ukuphuma komntwana. Nangona ukuphela komzimba kubonakala njengengxaki kubasetyhini abadala, abaninzi abasetyhini abancinane abafumana ukuphuma kwimihla yokuphuphuma kwexesha bayazifumana bengalungelekanga utshintsho olungalindelekanga olwenzekayo.
I-Estrogen Crash ivela xa zombini i-ovaries i-ovari isuswe okanye ngokukhawuleza ukuyeka ukusebenza. Xa oku kwenzekayo umzimba uyayeka ukuvelisa i- estrogen .
Ngokwemvelo, abafazi be-menopausal bancipha ngokuthe gqolo kumazinga e-estrogen ngaphezu kwexesha lesibini ukuya kweyeshumi. Ngokwahlukileyo, ukuveliswa kwe-estrogen yabasetyhini abasebancinci abaye bafumana ukupheliswa komzimba okanye ukuphulukana kwe-ovariya kunqunyulwa ngokukhawuleza, "kusho uDkt. Lila Nachtigall, MD, uMlawuli Icandelo loLwazi lweNtombi eNew York University Medical School. "Isiphumo kukufika ngokukhawuleza nangokukhawuleza kweempawu ze-vasomotor: ukutshisa okutshisa, ukusalaza ebusuku , ukuphazamiseka kokulala kunye nokuma komzimba."
Abangaphezu kwesiqingatha sesigidi basetyhini bafumana ukunyuka kwamaxesha ngonyaka kwiUnited States kwaye ubuncinane ngaphezu kwesigamu se-hysterectomy kubandakanya i-oophorectomy ye-bilateral- ukususwa kwee-ovari. Ngaphezu kwe-20% yabasetyhini abaya kwi-oophorectomy yamazwe angama-40 bangaphantsi kwe-40. Ngomnye wabasetyhini abangama-100 baya kuphuhliswa kwe-ovarian failure phambi kweminyaka engama-40.
Ukuqeda isiXhosa kunye ne-Estrogen Crash
Abasetyhini abanamava okuyeka ukuhlala besesigxina baye bafumana ithuba lokuhlukumeza umama ngokugqithisileyo kubantu besetyhini abafumana ukuphela komntu ekudala. Ngokwemvelo yesikhashana, amanqanaba e-estrogen ayancipha kancane kancane kwixesha eliphakathi kweminyaka emi-2 ukuya kwe-10, ngelixa abesetyhini besifo se-menopausal badibana ne-esrogen ngokukhawuleza.
"Ngokuqhelekileyo, ibhinqa elihamba ngokunyuka komzimba liya kuba nelinye iimpawu ze-vasomotor ngokungaguqukiyo," kutsho uDkt. Lila Nachtigall. "Ingakumbi isigidimi sinokuba nenyanga embi apha okanye ikhona." Kodwa xa kukho i-oophorectomy yezizwe, iziphumo zigqithise kakhulu kwaye izigulane ezincinci, ngokukodwa, ziyakwazi ukuphendula. "
Kwindlela yokusebenza kukaDkt. Nachtigall, i-100% yabesifazane besifo se-menopausal babenempawu ze-vasomotor kwaye i-90% yabasetyhini bafumana iimpawu ezinzima eziye zaba neminyaka eyi-8.5. Ngokwahlukileyo, ngelixa amaninzi angama-85% asemasimini ase-menopausal ngokwemvelo atshayelwa ukushisa okukhulu, i-15% kuphela ibona iimpawu ezinzima. Ngelo xesha abafazi bafikelela kwimiqathango yokuphela komntu, malunga ne-43% ingxelo ingxelo ngokumalunga neempawu ezinzima ezithatha emva kweminyaka emi-2.
Abasetyhini abanamava emva kokuphuma komzimba emva kokuba i-oophorectomy yezizwe zihlala zigula ngokukhawuleza emva kokuhlinzwa ukugwinya iipilisi. Ngamaxesha amaninzi odokotela bachaza i-estrogen patch egubuke ekhumbeni kwaye ikhulula i-estrogen ngesikhumba ukuya kwigazi ngexesha leentsuku. Inzuzo yesiqhelo se-estrogen yonikezelo lwayo lwexesha.
Eyona ncinane kunazo zonke ezi zi-patvel i-Vivelle-Dot. Umthamo we -05 mg / ngosuku ubukhulu besitampu sokuposa kunye ne-75% encinci kunee-patrogen.
Igugile kwisisu esingaphansi apho ihambisa i-estradiol ngokusebenzisa iqhosha le-skin elidlulayo kwigazi. I-Estradiol yiyona isrogen eyona nto iveliswa ngama-ovari. I-Vivelle-Dot iyatshintshwa kabini ngeveki kwaye idlulela kwimvula, ukubhukuda, kunye neminye imisebenzi yansuku zonke ngaphandle kokuphuma. Isiqwenga sinika ukukhululeka ekukhanyeni okutshisayo, ukuthunga ebusuku, kunye nezinye iimpawu ze-Estrogen Crash okanye ukunyuka komzimba.
I-Vivelle-Dot ifumaneka kwamanye amandla amathathu; .0375, .075, kunye .1 mg / ngosuku. Iziphumo eziqhelekileyo ezichazwe ngokuqhelekileyo ziyizinwele ezincinci kunye nentlungu encinci yesikhumba.Iziganeko ezichaseneyo zesistim nge-Vivelle (R) * (i-estradiol transdermal system) kunye ne-placebo, ngokulandelanayo, ziquka intloko (36% vs 30%), isithintelo sebele (4.9% vs 1.1%), kunye nokugcinwa kwamanzi (3.8% vs.2.2%).
Ezinye izigulane ezithatha iVivelle-Dot (TM) 0.0375 mg / ngosuku zifumana ukuphuculwa kokubambezeleka kokusebenza.
Abasetyhini abathile akufanele basebenzise i-estrogens. Oku kuquka nabasetyhini abanolwazi okanye abanokukrokra ukukhulelwa, ukungagqithanga okwenziwe ngabangelwa ngumzimba, umhlaza wesibele, i-neoplasia exhomekeke kwi-estrogen, i-thrombophlebitis esebenzayo okanye iingxaki ze-thromboembolic, okanye imbali ebhaliweyo yale miqathango. I-Estrogens iye yaxelwa ukuba yandise umngcipheko we-endometrial carcinoma kuma-postmenerausal women.
UWeil Neil Jones, uMlawuli oyiNtloko weNtengiso kunye neNtengiso yeNoven Pharmaceuticals, Inc. ithi i-media kunye noluntu lwempilo yoluntu kufuneka luncede abancinci abasetyhini baqonde imiphumo engenzeka ye-Estrogen Crash ukwenzela ukuba bayakwazi ukwenza isigqibo esifanelekileyo ukuba bafumane bejongene kusasa.
I-Vivelle-Dot (TM) ithengiswa nguNovogyne Pharmaceuticals, intsebenziswano phakathi kweNovotis Pharmaceuticals Corporation yase-East Hanover, eNew Jersey, kunye neNoven Pharmaceuticals, Inc. yaseMiami, eFlorida.
* Ukuqulunqwa kwangaphambili (i-Vivelle) (R) evivinywe kwizilingo zeklinikhi iye yahlaziywa ukunciphisa ubukhulu bepatch kunye ne-formulation formulation (i-Vivelle-Dot) (TM) iboniswe ukuba ifaniswe ngokufanayo neyokuqulunqa kwangaphambili.
Umthombo wolwazi: PRNewswire / NEWSdesk